Fierce Pharma Asia—BioNTech's Asia expansions; Takeda's debt plans; AZ-Daiichi ADC's breast cancer data

BioNTech and Fosun Pharma, Takeda, AstraZeneca and Daiichi Sankyo made our news this week. (Google)
BioNTech is expanding in Asia with a planned regional headquarters and mRNA manufacturing facility in Singapore, plus a joint venture with Fosun Pharma focused on its COVID-19 vaccine in China. Takeda believes revenues from its remaining portfolio can help it pay down debt and grow into the future. Daiichi Sankyo and AstraZeneca's anti-TROP2 antibody-drug conjugate reported early tumor shrinkage data. And more.
With cash flow from selling its COVID-19 vaccine, BioNTech aims to become a “global immunotherapy powerhouse.” After setting up new operations in Europe and the U.S., the mRNA specialist is targeting Asia. It will set up a Southeast Asia regional headquarters in Singapore, accompanied by an mRNA manufacturing facility that could eventually boast an estimated annual capacity of several hundred million doses of mRNA shots.

Related Keywords

China ,India ,Singapore ,Chinese ,Sun Pharma ,Christophe Weber ,Daiichi Sankyo ,Eli Lilly ,Yizhe Wang ,Fosun Pharma ,Pfizer ,Astrazeneca ,Gilead Sciences ,Merck Co ,Bristol Myers Squibb ,Cipla ,Southeast Asia ,Biontech ,Shanghai Fosun Pharmaceutical Group ,Makeda ,Olumiant Baricitinib ,Covid 19 ,Vaccine Manufacturing ,Antibody Drug Conjugates ,Triple Negative Breast Cancer ,Icensing ,Pharma ,சீனா ,இந்தியா ,சிங்கப்பூர் ,சீன ,சூரியன் பார்மா ,கிறிஸ்டோஃப் வெபர் ,தய்ச்சி சாங்கியோ ,எலி லில்லி ,ஃபைசர் ,கிலியட் அறிவியல் ,மெர்க் இணை ,பிரிஸ்டல் மைஸ் ஸ்க்விப்ப் ,சிப்லா ,தென்கிழக்கு ஆசியா ,ஹினா ,ந்திய ,பார்மா ,